Abstract
PURPOSE: It tends not only to shed lights on an emerging classification framework of disease according to the shared molecular pathogenesis across various organs/tissues, but also to inspire more efficient paradigms of pharmaceutic innovation in a broader medical perspective. METHODS: Literature review and re-thinking. RESULTS: This article has sorted out an updated profile of the outstanding targeted medications with an extending list of clinical indications in oncology and beyond. CONCLUSION: Pharmaceutic development can be processed in a less risky and more affordable manner through drug repurpose or tissue agnostic approval.